[go: up one dir, main page]

WO2016090371A3 - Procédés et compositions d'activation de la ligase parkin - Google Patents

Procédés et compositions d'activation de la ligase parkin Download PDF

Info

Publication number
WO2016090371A3
WO2016090371A3 PCT/US2015/064305 US2015064305W WO2016090371A3 WO 2016090371 A3 WO2016090371 A3 WO 2016090371A3 US 2015064305 W US2015064305 W US 2015064305W WO 2016090371 A3 WO2016090371 A3 WO 2016090371A3
Authority
WO
WIPO (PCT)
Prior art keywords
parkin ligase
compositions
activation methods
methods
parkin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/064305
Other languages
English (en)
Other versions
WO2016090371A2 (fr
Inventor
Jennifer Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
An2h Discovery Ltd
Original Assignee
An2h Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP15865563.9A priority Critical patent/EP3227437A4/fr
Application filed by An2h Discovery Ltd filed Critical An2h Discovery Ltd
Priority to CA2968094A priority patent/CA2968094A1/fr
Priority to MX2017007095A priority patent/MX2017007095A/es
Priority to CN201580075270.1A priority patent/CN107249580A/zh
Priority to BR112017011644A priority patent/BR112017011644A2/pt
Priority to AU2015357487A priority patent/AU2015357487A1/en
Priority to KR1020177018198A priority patent/KR20170092634A/ko
Priority to JP2017530205A priority patent/JP2017538699A/ja
Publication of WO2016090371A2 publication Critical patent/WO2016090371A2/fr
Publication of WO2016090371A3 publication Critical patent/WO2016090371A3/fr
Priority to IL252425A priority patent/IL252425A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)

Abstract

La présente invention concerne des procédés et des compositions permettant d'activer une ligase Parkin par l'administration à un sujet le nécessitant d'une quantité thérapeutiquement efficace d'un composé qui rompt au moins un doigt de zinc de la ligase Parkin. La présente invention concerne également des procédés de traitement et/ou de réduction de l'incidence de maladies ou d'affections associées à l'activation de la ligase Parkin.
PCT/US2015/064305 2014-12-05 2015-12-07 Procédés et compositions d'activation de la ligase parkin Ceased WO2016090371A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2017530205A JP2017538699A (ja) 2014-12-05 2015-12-07 パーキンリガーゼ活性化の方法及び組成物
CA2968094A CA2968094A1 (fr) 2014-12-05 2015-12-07 Procedes et compositions d'activation de la ligase parkin
MX2017007095A MX2017007095A (es) 2014-12-05 2015-12-07 Metodos y composiciones de activacion de la ligasa parkin.
CN201580075270.1A CN107249580A (zh) 2014-12-05 2015-12-07 帕金连接酶活化方法和组合物
BR112017011644A BR112017011644A2 (pt) 2014-12-05 2015-12-07 métodos e composições de ativação da ligase parkina
EP15865563.9A EP3227437A4 (fr) 2014-12-05 2015-12-07 Procédés et compositions d'activation de la ligase parkin
KR1020177018198A KR20170092634A (ko) 2014-12-05 2015-12-07 파킨 리가제 활성화 방법 및 조성물
AU2015357487A AU2015357487A1 (en) 2014-12-05 2015-12-07 Parkin ligase activation methods and compositions
IL252425A IL252425A0 (en) 2014-12-05 2017-05-22 Methods for activating parkin ligase and preparations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462087972P 2014-12-05 2014-12-05
US62/087,972 2014-12-05
US201562222008P 2015-09-22 2015-09-22
US62/222,008 2015-09-22
US201562237400P 2015-10-05 2015-10-05
US62/237,400 2015-10-05

Publications (2)

Publication Number Publication Date
WO2016090371A2 WO2016090371A2 (fr) 2016-06-09
WO2016090371A3 true WO2016090371A3 (fr) 2016-07-28

Family

ID=56092683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/064305 Ceased WO2016090371A2 (fr) 2014-12-05 2015-12-07 Procédés et compositions d'activation de la ligase parkin

Country Status (11)

Country Link
US (2) US10155936B2 (fr)
EP (1) EP3227437A4 (fr)
JP (1) JP2017538699A (fr)
KR (1) KR20170092634A (fr)
CN (1) CN107249580A (fr)
AU (1) AU2015357487A1 (fr)
BR (1) BR112017011644A2 (fr)
CA (1) CA2968094A1 (fr)
IL (1) IL252425A0 (fr)
MX (1) MX2017007095A (fr)
WO (1) WO2016090371A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3227437A4 (fr) 2014-12-05 2018-08-22 An2H Discovery Limited Procédés et compositions d'activation de la ligase parkin
US10442817B2 (en) * 2015-06-04 2019-10-15 Drexel University Inhibitors of RAD52 recombination protein and methods using same
GB201514015D0 (en) * 2015-08-07 2015-09-23 Arnér Elias S J And Dept Of Health And Human Services Novel pyridazinones and their use in the treatment of cancer
CN114668761B (zh) * 2015-10-23 2025-08-01 威佛（国际）股份公司 新的膜铁转运蛋白抑制剂
CA3066110A1 (fr) 2016-06-03 2017-12-07 An2H Discovery Limited Derives de triazole benzamide et compositions et procedes de traitement associes
CA3032136A1 (fr) 2016-07-28 2018-02-01 Mayo Foundation For Medical Education And Research Activateurs de petites molecules de la fonction enzymatique de la parkine
WO2018178237A1 (fr) * 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour le traitement de maladies génétiques mitochondriales
CN109745324A (zh) * 2017-11-06 2019-05-14 中国科学院上海生命科学研究院 非经典NF-kB通路的小分子抑制剂及其应用
WO2019100106A1 (fr) * 2017-11-24 2019-05-31 The University Of Sydney Composés antibactériens et leurs procédés d'utilisation
US10889553B2 (en) 2017-12-01 2021-01-12 Nysnobio Ireland Dac Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same
CN109988157B (zh) * 2018-01-03 2022-12-27 四川大学 新型小分子化合物、制备方法及在制备抗耐药结核分枝杆菌等分枝杆菌药物方面的用途
EP3758697B1 (fr) * 2018-02-28 2024-10-16 Crestone, Inc. Nouveaux amides hétérocycliques anti-mycobactériens
WO2019204815A1 (fr) * 2018-04-20 2019-10-24 An2H Discovery Limited Procédés de traitement de patients atteints d'un cancer ayant des déficiences de la régulation de la cycline d
MX2020014070A (es) * 2018-06-19 2021-05-27 Univ Pablo De Olavide Composiciones para tratar y/o prevenir enfermedades por agregación de proteínas.
KR102066842B1 (ko) * 2018-08-09 2020-01-17 대한민국 10-debc 또는 이의 약학적으로 허용가능한 염을 포함하는 결핵의 예방 또는 치료용 약학적 조성물
KR102091336B1 (ko) * 2018-10-30 2020-03-19 건국대학교 산학협력단 펩타이드 디포밀라아제 활성 저해용 화합물 및 이를 포함하는 조성물
IL264854A (en) * 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
JP2022552792A (ja) * 2019-10-01 2022-12-20 ドレクセル ユニバーシティ Ｒａｄ５２のキノリン阻害剤及び使用方法
KR102816558B1 (ko) * 2019-11-05 2025-06-05 아주대학교산학협력단 종양 괴사 인자 알파(TNF-α) 소분자 억제제
JP2022012379A (ja) * 2020-07-01 2022-01-17 国立大学法人富山大学 ユビキチン－プロテアソーム系の活性化剤、およびその利用
GB202013728D0 (en) * 2020-09-01 2020-10-14 Nrg Therapeutics Ltd Novel compounds
CN118593495A (zh) * 2024-06-05 2024-09-06 兰州大学 喹啉生物碱衍生物在制备治疗癌症药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817675A (en) * 1993-07-05 1998-10-06 Diomed Developments Limited Compositions for the treatment of psoriasis and their use
KR20100015088A (ko) * 2008-08-04 2010-02-12 한국생명공학연구원 세포외 신호조절 키나제의 활성을 저해하는트리아졸릴-벤즈아미드 유도체 또는 이의 약학적으로허용가능한 염을 유효성분으로 함유하는 암 또는 심혈관계질환의 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047631A2 (fr) 2004-10-25 2006-05-04 University Of Medicine And Dentistry Of New Jersey Composes antimitotiques antiproliferatifs
WO2008134474A2 (fr) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions et procédés comportant des inducteurs de mort cellulaire et d'activation de procaspase
EP2158487A1 (fr) * 2007-05-21 2010-03-03 Elan Pharma International Limited Substrat et dosage de la parkine
WO2008157131A1 (fr) 2007-06-15 2008-12-24 Irm Llc Inhibiteurs de protéine kinase et procédés d'utilisation
EP2393794B1 (fr) 2009-02-09 2017-03-22 The Board of Trustees of the University of Illionis Conception, synthèse et évaluation de composés activateurs de procaspase en tant que médicaments anticancéreux personnalisés
EP2523949B1 (fr) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Nouveaux dérivés de triazole en tant que modulateurs de la secrétase gamma
WO2012044562A2 (fr) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Inhibiteurs de pyrazolopyrimidine pde10
US8603994B2 (en) 2010-11-11 2013-12-10 Valted, Llc Transcriptional repression leading to Parkinson's disease
US8916705B2 (en) 2011-10-14 2014-12-23 The Board of Trustees of The University of Illilnois Procaspase-activating compounds and compositions
FR2987537B1 (fr) 2012-02-23 2015-12-25 Cliris Procede et systeme de supervision d'une scene, notamment dans un site de vente
US9592229B2 (en) 2012-03-02 2017-03-14 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
ES2774930T3 (es) 2012-03-06 2020-07-23 Univ Illinois Activación de procaspasa 3 mediante terapia de combinación
JP6265558B2 (ja) 2012-08-03 2018-01-24 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 酵素活性化化合物及び組成物
US20150210717A1 (en) 2012-09-13 2015-07-30 Baden-Württemberg Stiftung Gmbh Specific inhibitors of protein p21 as therapeutic agents
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
EP3227437A4 (fr) 2014-12-05 2018-08-22 An2H Discovery Limited Procédés et compositions d'activation de la ligase parkin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817675A (en) * 1993-07-05 1998-10-06 Diomed Developments Limited Compositions for the treatment of psoriasis and their use
KR20100015088A (ko) * 2008-08-04 2010-02-12 한국생명공학연구원 세포외 신호조절 키나제의 활성을 저해하는트리아졸릴-벤즈아미드 유도체 또는 이의 약학적으로허용가능한 염을 유효성분으로 함유하는 암 또는 심혈관계질환의 예방 또는 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG ET AL.: "ERK-mediated phosphorylation of TFAM downregulates mitochondrial transcription: implications for Parkinson's disease.", MITOCHONDRION, vol. 17, July 2014 (2014-07-01), pages 132 - 140, XP029043651 *

Also Published As

Publication number Publication date
US20160160205A1 (en) 2016-06-09
US20200087648A1 (en) 2020-03-19
IL252425A0 (en) 2017-07-31
CN107249580A (zh) 2017-10-13
EP3227437A4 (fr) 2018-08-22
JP2017538699A (ja) 2017-12-28
US10155936B2 (en) 2018-12-18
MX2017007095A (es) 2017-11-17
WO2016090371A2 (fr) 2016-06-09
BR112017011644A2 (pt) 2018-02-14
CA2968094A1 (fr) 2016-06-09
KR20170092634A (ko) 2017-08-11
EP3227437A2 (fr) 2017-10-11
AU2015357487A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
WO2016090371A3 (fr) Procédés et compositions d'activation de la ligase parkin
WO2015185875A9 (fr) Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs
WO2015023976A3 (fr) Inhibiteurs sélectifs de la grp94 et leurs utilisations
EP2968404A4 (fr) Compositions comprenant du sélénium et utilisation de celles-ci pour le traitement et la prévention de maladie ou d'états associés avec un dysfonctionnement mitochondrial
NZ739392A (en) Methods for treating hepcidin-mediated disorders
WO2015127134A3 (fr) Anticorps anti-composant c5 de du systeme de complement
WO2017019540A3 (fr) Inhibiteurs de glycosylation à liaison en n et procédés les utilisant
EP3182989A4 (fr) Méthodes et compositions destinées à prévenir et à traiter une maladie
EP4609911A3 (fr) Composés efficaces pour traiter l'hépatotoxicité et des stéatoses hépatiques, et utilisations de ceux-ci
EP3268007A4 (fr) Compositions et procédés thérapeutiques pour le traitement de maladies associées au complément
WO2014150925A3 (fr) Palbociclib deutéré
HK1256042A1 (zh) 用於治疗糖尿病周围神经病变的hdac抑制剂
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
EP3261446A4 (fr) Méthodes et compositions permettant le traitement ou la prévention de la maladie de parkinson
WO2015134603A3 (fr) Procédés de traitement du cancer
EP3261655A4 (fr) Compositions et méthodes pour le traitement de "plaques" et de "noeuds" chez les êtres humains et les animaux
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
WO2015095789A3 (fr) Suppression de l'inflammation et de l'hyperréactivité pulmonaires allergiques
EP3065548A4 (fr) Composés inhibiteurs de fibrose et leurs méthodes d'utilisation pour prévenir ou traiter les maladies fibrotiques
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
EP3534924A4 (fr) Composition pour la prévention et/ou le traitement de maladies cardiovasculaires
WO2016038040A3 (fr) Composés dipeptidyl-cétoamide et leur utilisation pour le traitement et/ou la prévention de l'accumulation de graisse
WO2015113041A3 (fr) Compositions et procédés de traitement de maladies autoimmunes et inflammatoires
HK40040367A (en) Compositions and methods relating to the treatment of diseases
LT3796897T (lt) Junginiai, skirti odos ar gleivinės pažeidimų prevencijai ir gydymui, turintys uždegiminį komponentą

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15865563

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2968094

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 252425

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2017530205

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015865563

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/007095

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015357487

Country of ref document: AU

Date of ref document: 20151207

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017011644

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20177018198

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017011644

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170601